Amid controversy over access to a lifesaving tuberculosis pill, a new contracting effort is expected to lower the price for the medicine by as much as 55% in dozens of low- and middle-income countries, according to a group that administers a global fund for distributing TB drugs. But advocacy groups continue to argue that Johnson & Johnson, which makes the pill, has stymied wider access.
At issue is the cost of bedaquiline, which is the backbone of different combination therapies used to treat multi-drug-resistant tuberculosis. But ever since the pill was approved for this purpose more than a decade ago, a combination of pricing and patent policies pursued by J&J have made it hard for numerous lower-income countries to obtain the medication.
Over the past few years, the company took various steps to blunt criticism by lowering the price. In July, J&J reached a deal with the Stop TB Partnership, which was created by the United Nations, to allow generic companies to make cheaper versions in dozens of low- and middle-income countries. Yet advocacy groups argued barriers still remained for many countries with limited resources.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect